NVTAのチャート
NVTAの企業情報
| symbol | NVTA |
|---|---|
| 会社名 | Invitae Corp （NVTA インビティ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 インビタエ(Invitae Corporation)はデオキシリボ核酸（DNA）含有試料を処理し、患者固有の遺伝子変異に関する情報を分析し、臨床医およびその患者向けの試験報告書を生成するための、実験室プロセス、ソフトウェアツールおよび情報科学機能の統合ポートフォリオを利用する。同社の製品は、遺伝性がん、神経障害、心血管障害、小児障害およびその他の遺伝病を含む複数の適応症に使用できる1100以上の遺伝子を含むアッセイで構成される。同社はがん、心臓病、神経筋、小児および希少疾患における遺伝的条件についてパネルを提供する。同社は遺伝子検査、ゲノムネットワーク、ゲノム管理に重点を置く。同社は全ての試験の標準として完全な遺伝子シークエンシングおよび欠失・複製分析を提供している。同社は患者中心のデータ会社であるAltaVoiceに持分を有する。 インビティは、米国の遺伝子診断サ―ビス会社。病院や診療所などの医療機関に、遺伝子診断サ―ビスを提供する。遺伝性の乳がん、腸がん、前立腺がんなどの診断を目的とした遺伝子検査サ―ビスのほか、消費者向け遺伝子検査キットの開発・製造・販売も行う。本社は、カリフォルニア州サンフランシスコ。 invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people. |
| 本社所在地 | 415 374-7782 |
| 代表者氏名 | Randal W. Scott |
| 代表者役職名 | Executive Chairman of the Board |
| 電話番号 | +1 415-374-7782 |
| 設立年月日 | 40179 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 788人 |
| url | www.invitae.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） -109.05700 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 1978.53800 |
| 売上高 | 売上高（百万ドル） 147.69900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1930.44200 |
| 当期純利益 | 当期純利益（百万ドル） -129.35500 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 InVitae Corp revenues increased from $68.2M to $147.7M. Net loss before extraordinary items increased 73% to $129.4M. Revenues reflect United States segment increase from $62.4M to $138.2M Rest of World segment increase from $2.5M to $5.3M. Higher net loss reflects Selling and Marketing - Balancing value increase of 41% to $69.5M (expense). |
NVTAのテクニカル分析
NVTAのニュース
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today? 2023/06/06 20:15:10 InvestorPlace
An upcoming event has gene editing stocks rising today. Editas Medicine (NASDAQ: EDIT ) has announced plans to present some important trial data via a live webinar next week on June 12 at 8 a.m. Eastern, the clinical-stage genome editing company will present the clinical data from its RUBY trial of EDIT-301 as a treatment for severe sickle cell disease. In a statement released by the company, Editas also noted that it will present “initial clinical data from the EDITHAL trial of EDIT-301 for the treatment of transfusion-dependent beta thalassemia.” News of this event has kept EDIT stock in the green all day, indicating that the market is reacting well. Does this mean that this positive momentum will continue as the webinar date draws closer? Let’s take a closer look at the event and assess what investors should be expecting. What’s Happening With Gene Editing Stocks Editas isn’t the only company benefitting from this announcement. Several other gene editing stocks are on the rise, one of which is outperforming EDIT.
Invitae to Present at the William Blair 43rd Annual Growth Stock Conference 2023/05/31 10:59:00 PR Newswire
SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 12:40 p.m….
Invitae CFO Wen resigning to pursue other opportunities, appoints Christine Gorjanc as interim CFO 2023/05/26 06:03:20 Seeking Alpha
Invitae (NVTA) notifies that Chief Financial Officer Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023. A search for successor is underway. Ms
SNDL, Invitae among additions to Russell microcap; Inovio, Bionano among deletions 2023/05/24 17:33:04 Seeking Alpha
In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index
Invitae to appeal verdict in Natera patent case 2023/05/15 20:59:32 Seeking Alpha
Invitae (NVTA) said it will appeal a verdict in a patent case in a federal court in Delaware that found in favor of Natera (NTRA). Read more here.
Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023 2023/04/26 10:59:00 PR Newswire
SAN FRANCISCO, April 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30…
Why Shares of Invitae Soared on Friday 2023/04/22 01:52:11 The Motley Fool
Ark Innovation CEO Cathie Wood said the stock is undervalued.
Futures Slide In Risk-Off End To Volatile Week 2023/04/21 11:58:00 Zero Hedge
Futures Slide In Risk-Off End To Volatile Week US equity futures extended their recent weakness and traded near the week''s lows in early Friday trading as investors digested the latest corporate updates. Investors now await PMI data later today for further direction on the path for monetary policy. Contracts on the S&P 500 and the Nasdaq 100 drifted -0.2% lower as of 7:15 a.m. ET, as both indexes were set to end the week in negative territory, the Nasdaq underperforming slightly. Treasury yields edged higher, while the dollar advanced against other major currencies with a measure of its strength set for its first weekly gain in six weeks. Iron ore, gold and oil all decline, as the gains from the latest OPEC+ output cut are now all gone: so will OPEC cut again to reverse the slide in the one asset class that unlike stocks, everyone loves to short as a hedge for the coming recession? In premarket trading, Tesla edged higher after the electric-vehicle maker increased prices of its Model S and X vehicles in the United States just two days after cutting prices.
Invitae, CSX And Other Big Stocks Moving Higher In Friday''s Pre-Market Session 2023/04/21 10:39:05 Benzinga
U.S. stock futures traded mixed this morning. Here are some big stocks recording gained in today’s pre-market trading session. Mullen Automotive, Inc. (NASDAQ: MULN ) shares jumped 30.2% to $0.1103 in pre-market trading after dropping around 6% on Thursday. ContextLogic Inc. (NASDAQ: WISH ) gained 21% to $8.69 in pre-market trading after the company announced a $50 million buyback program. Atai Life Sciences N.V. (NASDAQ: ATAI ) gained 8.6% to $2.38 in pre-market trading after gaining around 7% on Thursday. Invitae Corporation (NYSE: … Full story available on Benzinga.com
Invitae Shares Surge On Cathie Wood Comments: Here''s What The Ark Invest CEO Said 2023/04/20 20:58:19 Benzinga
Invitae Corp (NYSE: NVTA ) shares are taking off … Full story available on Benzinga.com
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases 2023/03/22 11:30:00 PR Newswire
The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield''s expertise in drug discovery to address high unmet needs among rare disease patients SAN FRANCISCO, March 22, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical…
Invitae, Epic team up to simplify access to genetic test results 2023/03/21 16:08:50 Seeking Alpha
Genetics company Invitae (NVTA) said it is collaborating with healthcare software company Epic to streamline genetic testing
Invitae Announces Partnership with Epic to Streamline Genetic Testing 2023/03/21 11:30:00 Invitae
Invitae (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company. Through Aura, Epic''s specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers'' usual workflows so that it''s easier to use genetic insights to inform treatment decisions. "Genetic testing can inform some of the most important care decisions in patients'' lives, and Invitae is making it more accessible to both patients and providers across the Epic community," said Dave Fuhrmann, senior vice president of research and development at Epic. "Aura will help them do so by further enabling precision medicine at many of the nation''s leading healthcare organizations." "Our use of Aura allows patients and providers to seamlessly access genetic testing that can help identify at-risk individuals, enhance early detection and better
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology 2023/03/16 11:30:00 Kwhen Finance
Our Attention Has Been Attracted to Invitae Corporation (NYSE:NVTA) 2023/03/13 18:08:00 US Post News
Invitae Corporation (NVTA)’s stock has witnessed a price hike of 2.60% from the previous close with its current price standing at $1.45. Its current price is -84.24% under its 52-week high of $9.18 and 6.37% more than its 52-week low of $1.36. Based on the past 30-day period, the stock price is -39.32% below the […]